Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL

Decera Clinical Education Oncology Podcast · Aug 26, 2020 · 31m

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:

ASCEND: acalabrutinib vs idelalisib plus rituximab or BR

ACE-CL-001: acalabrutinib long-term efficacy

CLL14: Venetoclax plus obinutuzumab

CLARITY: Ibrutinib plus venetoclax

Measurable residual disease (MRD)

Complex karyotypes

Zanubrutinib plus obinutuzumab and venetoclax

Presenters:

Jennifer R. Brown, MD, PhD

Associate…